OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology

BATON ROUGE, LA OBMP, (Marketwired December 12, 2016) OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ( OncBioMune or the Company ), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the European Patent Office has approved the Company s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine. The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune s protein
http://bit.ly/2hpzoa7